Umbralisib

厄布利塞

Report date: 2024/07/18 15:42:39
NME

Base Information

Drug NameUmbralisib
Drug Alias NameUkoniqTGR-1202RP-5264RP 5307
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsCasein kinase I isoform epsilon inhibitorsCell proliferation inhibitors
TargetsPhosphatidylinositol 3 kinase deltaCasein kinase I isoform epsilon
Therapy Area/IndicationsRichter's SyndromePancreatic NeoplasmsStomach Neoplasms +[18] 
Global Approved IndicationsLymphoma, FollicularLymphoma, B-Cell, Marginal Zone
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/02/05
Country/TerritoryUnited StatesSlovakiaPoland +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRhizen Pharmaceuticals SaTg Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe University Of ChicagoTg Therapeutics Inc
Inactive CompaniesH Lee Moffitt Cancer Center & Research InstituteColumbia UniversityNational Cancer Institute +[6] 
Active IndicationsRichter's SyndromeWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell +[5] 
Inactive IndicationsPancreatic NeoplasmsStomach NeoplasmsRectal Neoplasms +[13] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG